Genetic Screening and Investigating the Effect of Assisted Oocyte Activation in Couples With Diminished/Aberrant Embryonic Development.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Embryo
- Sponsor
- University Hospital, Ghent
- Enrollment
- 42
- Locations
- 1
- Primary Endpoint
- Blastocyst rate
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This is an interventional comparative study at the Department of Reproductive Medicine at Ghent University Hospital. Patients with previous embryo developmental problems are eligible for the study. Patients will undergo an ICSI-AOA treatment and will also be screened for genes important in the oocyte activation and embryonic development process. Also, the calcium releasing pattern of the patients' spermatozoa will be investigated.
Detailed Description
Assisted Oocyte Activation (ICSI-AOA) will be the treatment for these patients to overcome their previous embryo developmental problems. This protocol artificially induces calcium rises in the oocyte, which mimics the natural oocyte activation process induced by the sperm factor PLCzeta. If 6 or more mature oocytes are collected at oocyte retrieval, 50%ICSI and 50% ICSI-AOA will be applied to all oocytes. The best embryo(s) will be transferred back. Rest embryo(s) will be vitrified for future cycles. Patients will be followed up. Furthermore, an additional sperm sample will be produced to investigate the calcium inducing pattern of the patients' spermatozoa. Thereby, mouse and/or human (research-donated control oocytes) will be pre-incubated with a Ca2+ sensitive dye. Next, human spermatozoa will be injected into these mouse/human oocytes and the calcium pattern will be recorded under an inverted epifluorescence microscope. Both partners will give a saliva sample to screen for mutations possible genes involved in oocyte activation and embryo development.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients with one or more previous ICSI cycles (UZ Gent) AND
- •patients with:
- •complete developmental arrest (no transfer), or
- •complete developmental delay (no morula/blastocyst on Day 5), or
- •significantly reduced blastocyst formation (≤15%)
- •willing and able to give informed consent
Exclusion Criteria
- •patients which went for oocyte or sperm donation
- •patients with severe male infertility or low fertilization (\<33%) after ICSI
- •cycles requiring surgical sperm recovery procedures
Outcomes
Primary Outcomes
Blastocyst rate
Time Frame: 5 days after oocyte retrieval
Blastocyst rate will be calculated and blastocyst will be scored. The best quality embryos will be transferred and/or frozen.
Secondary Outcomes
- Live birth rate(37 - 42 weeks after last menstruation)
- Pregnancy rate(Positive hCG 16 days after oocyte retrieval)